Parkinson's cell therapy development is examined in this piece. It highlights safety considerations and the tension between personalized and off-the-shelf strategies.
Key Takeaways
- UniXell obtained US IND clearance and Chinese NMPA approval for UX-DA003
- Preclinical data showed only 0.23% of transplanted cells remained proliferative after six months
- Company is pursuing parallel autologous and allogeneic iPSC development strategies